Eurand: Represented this Amsterdam-based specialty pharmaceutical company in its $123 million IPO.

Synageva BioPharma Corp.: Represented the underwriters, led by Goldman, Sachs & Co., in a $308 million offering of Synageva’s common stock.

Teva Pharmaceutical Industries Ltd.: Represented Teva, the leading generic pharmaceutical company in the world with a large specialty medicines business, in the following offerings:

• Three multi-tranche, multi-market offerings of senior notes aggregating $20.4 billion to finance its pending acquisition of Actavis Generics, the worldwide generic pharmaceutical business of Allergan plc.
• $6.75 billion aggregate stock offerings supporting its pending acquisition of Actavis Generics.
• €2 billion multi-tranche Eurobond offering.
• $1.3 billion debt tender offer for five series of senior notes.

Teva Pharmaceutical Industries Ltd.: Represented Teva, the leading generic pharmaceutical company in the world with a large specialty medicines business, in:

• $33.75 billion acquisition financing commitment, whereby the lenders have committed to provide Teva (i) up to $27 billion in loans under a senior unsecured Bridge Loan Credit Facility and (ii) up to $6.75 billion in loans under an Equity Bridge Loan Credit Facility.
• $1.0 billion five-year term loan facility.

• Confidential matters providing opinions and strategic advice on biosimilar patents
• Genentech v. Pfizer (D. Del.) (Herceptin) (trastuzumab) (pending)
• Amgen v. Hospira (D. Del.) (Epogen) (erythropoietin) (split decision in first U.S. jury trial under BPCIA; post-trial briefing pending)
• Amgen v. Hospira (Fed. Cir.) (Epogen) (erythropoietin) (favorable decision upholding district court on BPCIA issue of first impression)
• Hospira v. Genentech (USPTO) (Avastin) (bevacizumab) (favorable PTAB IPR decision)
• Hospira v. Genentech (USPTO) (Protein A chromatography) (favorable PTAB IPR decision)
• Takeda v. Array Biopharma (USPTO) (appeal pending after favorable IPR decision)
• Merck v. Hospira (D. Del.) (Invanz) (ertapenem) (appellate decision affirming favorable trial decision)
• Par v. Hospira (D. Del.) (Adrenalin) (epinephrine) (pending)
• Belcher v. Hospira (D. Del.) (Epinephrine Injection USP) (epinephrine) (pending)
• Vivus v. Actavis (D. Del.) (Qsymia) (pherntermine/ topiramate) (settled)
• Merck v. Amneal (Fed. Cir.) (Nasonex) (mometasone) (pending)
• Millennium Pharms. v. Sandoz and Hospira (Fed. Cir.) (Velcade) (bortezomib) (pending)
• Purdue v. Amneal (Fed. Cir.) (OxyContin) (oxycodone) (judgment of invalidity affirmed)
• Allergan v. UCB (E.D. Tex.) (Neupro) (rotigotine) (settled)
• Hospira v. Eurohealth (D. Del.) (Precedex) (dexmedetomidine) (settled)
• Hospira v. Intas (M.D.N.C.) (Precedex) (dexmedetomidine) (settled)
• Abbott v. Hospira (D. Del.) (Zemplar) (paricalcitol) (favorable judgment of non-infringement)
• Shire v. Neos (N.D. Tex.) (Adderall XR) (mixed amphetamines) (settled)
• Galderma v. Actavis (N.D. Tex.) (EpiDuo) (adpalene/benzoyl peroxide) (settled)
• Hospira v. Sandoz (D.N.J.) (Precedex) (dexmedetomidine) (settled)
• Hospira v. Sun Pharm. (E.D. Mich.) (Precedex) (dexmedetomidine) (settled)
• Nautilus Neurosciences v. Wockhardt (D.N.J.) (Cambia) (diclofenac sachet) (settled)
• Nautilus Neurosciences v. Edict (D.N.J.) (Cambia) (diclofenac sachet) (settled)
• Shire v. Watson (S.D.N.Y.) (Adderall XR) (mixed amphetamines) (settled) 

Merck & Co., Inc.: Represented the independent directors of Merck in connection with derivative litigation arising out of the marketing and use of Vioxx.

Teva Pharmaceutical Industries Ltd.: Represented Israel-based Teva, the leading generic pharmaceutical company and one of the top 15 pharmaceutical companies in the world, as well as in the following litigation:

• Meijer, Inc. v. Teva Pharmaceutical Industries Ltd.: Secured dismissal for Teva in class action and opt-out litigation seeking treble damages and injunctive relief in connection with allegations that generic drug manufacturers allocated the market for a hypertension drug, resulting in inflated prices.
• Purdue Pharma v. Teva Pharmaceuticals USA.
• Teva Pharmaceutical Industries Ltd. v. SmithKline Beecham Corp.: Successful representation of Teva in suit against SmithKline for prosecuting sham patent infringement litigation in violation of Section 2 of the Sherman Act.

Aegerion/Novelion Therapeutics/Amryt Pharma: Represented global biopharmaceutical company Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.

Allergan/Pfizer: Represented Morgan Stanley as financial advisor to Allergan in its agreement to combine with Pfizer for an enterprise value of approximately $160 billion.

Aralez Pharmaceuticals: Represented Aralez Pharmaceuticals in the following M&A-related transactions:

• AstraZeneca: Represented Aralez in its acquisition of the U.S. rights to beta-blocker Toprol-XL® from AstraZeneca.
• Merck: Represented Aralez in its acquisition of the U.S. and Canadian rights to cardiovascular drug Zontivity from Merck.

ARIAD Pharmaceuticals/Takeda/Sarissa Capital Management: Represented Sarissa Capital Management, the largest shareholder of ARIAD Pharmaceuticals, in connection with ARIAD’s agreement to be acquired by Takeda Pharmaceutical Company Limited for approximately $5.2 billion.

Auxilium/Endo International: Represented Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, in its proposed $2.6 billion acquisition by Endo International plc for a combination of cash and stock.

Ekkio Capital/Amatasigroup/Eurofins: Represented Ekkio Capital on the pending sale of Amatsigroup to Eurofins, the world leader in bio-pharmaceutical testing and a world leader in analytical services.

Ekkio Capital/Audevard: Represented Ekkio Capital in its acquisition of Audevard, a veterinary pharmaceutical company focused on the equine field.

Melinta Therapeutics/Cempra, Inc.: Represented Melinta Therapeutics, Inc. and Vatera Healthcare partners, Melinta’s majority shareholder, in Melinta’s agreement to merge with Cempra, Inc., forming a leading, vertically integrated commercial-stage anti-infectives company.

Melinta Therapeutics/Infectious Disease Business of The Medicines Company: Represented Melinta Therapeutics, Inc, in its pending acquisition the infectious disease business from The Medicines Company.

Mylan/Pfizer Upjohn: Represented Centerview Partners and PJT Partners as financial advisors to Mylan in its agreement to combine with Upjohn, Pfizer's off-patent branded and generic medicines business, to create a new pharmaceutical company.

NeuroDerm/Mitsubishi Tanabe Pharma Corporation: Represented Centerview Partners, financial advisor to NeuroDerm Ltd, in NeuroDerm’s deal to be acquired by Mitsubishi Tanabe Pharma Corporation for $1.1 billion.

PAI Partners/Ethypharm: Represented PAI Partners in its negotiations to acquire European specialty pharma company Ethypharm from Astorg.

RIEMSER Pharma/Intrapharm Laboratories: Represented RIEMSER Pharma GmbH, a German specialty pharmaceutical company backed by Ardian, in its acquisition of British specialty pharmaceutical company Intrapharm Laboratories Ltd.

RIEMSER Pharma/Keocyt: Advised RIEMSER Pharma GmbH in its acquisition of French specialty pharmaceutical company Keocyt.

Salix Pharmaceuticals/Valeant Pharmaceuticals: Represented Centerview Partners as financial advisor to Salix Pharmaceuticals, a leader in the gastrointestinal market, in its agreement to be acquired by Valeant Pharmaceuticals for a total enterprise value of approximately $15.8 billion.

Sanofi-Aventis/Hoechst AG: Represented Sanofi-Aventis, the world’s largest pharmaceutical company, in its mandatory offer to shareholders of Hoechst.

Tesaro/GlaxoSmithKline: Represented Centerview Partners as financial advisor to oncology-focused biopharmaceutical company Tesaro in its acquisition by GlaxoSmithKline for $5.1 billion.

Vatera/CVC/Alvogen: We represented Vatera Healthcare Partners as part of the investment consortium led by CVC Capital Partners in the acquisition of a controlling stake in Alvogen, a high-growth pharmaceutical company, from Pamplona Capital Management.

Voalte/Hill-Rom: Represented Voalte, a pioneer and leader in real-time, mobile healthcare communications, in its sale to global medical technology company Hill-Rom for $180 million.

Warburg Pincus: Advised Warburg on numerous M&A-related transactions, including its investments in the following pharmaceutical companies:

• JHP Pharmaceuticals: Represented Warburg in connection with the approximately $490 million sale of JHP Pharmaceuticals, LLC to Par Pharmaceutical Companies.

• The Medicines Company: Advised Warburg in connection with its investment in The Medicines Company, a provider of cost-effective acute care products.

WuXi/Management-Led LBO: Represented the Special Committee of the Board of Directors of WuXi PharmaTech Inc. in its $3.3 billion management-led leveraged buyout, one of the largest going private transactions of a Chinese-based, U.S. listed company.

Genta Incorporated: Provided corporate representation on M&A and senior executive employment matters for the compensation committee of Genta, a biopharmaceutical company with a diversified portfolio of cancer treatment drug products.